464280 — TDSPharm Co Cashflow Statement
0.000.00%
- KR₩55bn
- KR₩31bn
- KR₩28bn
Annual cashflow statement for TDSPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | — | 3,456 | 4,688 | 3,718 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | — | 676 | 937 | 75.8 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 3,680 | -2,456 | -3,353 | -533 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Taxes Payable | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | 3,680 | 2,942 | 3,294 | 3,929 |
| Capital Expenditures | -201 | -631 | -271 | -717 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | -1,439 | -587 | -4,498 | -12,593 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -1,640 | -1,218 | -4,770 | -13,311 |
| Financing Cash Flow Items | — | — | — | -619 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | -2,757 | -410 | 175 | 12,450 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -717 | 1,315 | -1,301 | 3,068 |